Labels

PD-L1 and PD-1 Inhibitors Explained: What It Means, How It Is Tested and Why It Matters for Cancer Immunotherapy

PD-L1 is one of the most important biomarkers in modern cancer immunotherapy. But a PD-L1 result is often misunderstood. A positive result does not guarantee that immunotherapy will work, while a negative result does not necessarily mean that immunotherapy is impossible.

This SmartCancer guide explains what PD-L1 is, how the PD-1/PD-L1 immune checkpoint works, how PD-L1 is measured, what TPS and CPS mean, which cancers use PD-L1 testing, how PD-L1 influences immunotherapy decisions, why responses can occur despite low or negative PD-L1, and how PD-L1 fits into the broader precision-oncology biomarker landscape.

Quick definition: PD-L1, or programmed death-ligand 1, is a protein that can bind to PD-1 on T cells and suppress immune activity. Some cancers exploit this pathway to evade immune attack. Immune checkpoint inhibitors can block PD-1 or PD-L1 and restore T-cell activity against cancer cells. NCI describes PD-L1 as an immune-regulatory protein that can act as a brake on T-cell activity.

PD-L1 at a Glance

  • Full name: Programmed death-ligand 1
  • Gene: CD274
  • Protein type: Immune checkpoint ligand
  • Main receptor: PD-1
  • Primary biological role: Regulation of immune responses
  • Cancer relevance: Tumors can exploit PD-L1 signaling to suppress immune attack
  • Common clinical test: PD-L1 immunohistochemistry (IHC)
  • Common scoring systems: TPS and CPS, depending on cancer and assay
  • Main therapeutic connection: Immune checkpoint inhibitors
  • Important limitation: PD-L1 is an imperfect predictive biomarker
CANCER CELL / IMMUNE CELL
↓
PD-L1
↓
BINDS PD-1 ON T CELL
↓
T-CELL ACTIVITY IS SUPPRESSED
↓
IMMUNE EVASION

CHECKPOINT INHIBITOR
↓
BLOCKS PD-1 / PD-L1 SIGNALING
↓
T-CELL ACTIVITY CAN BE RESTORED

Table of Contents

What Is PD-L1?

PD-L1 stands for programmed death-ligand 1. It is a protein involved in regulation of the immune system.

PD-L1 can be expressed by normal cells as part of the body's mechanisms for controlling immune responses. Some cancers, however, can express PD-L1 and use the PD-1/PD-L1 pathway to reduce the ability of T cells to attack them.

According to the National Cancer Institute, when PD-L1 binds to PD-1 on T cells, the interaction can inhibit T-cell killing activity. Blocking this interaction with immune checkpoint inhibitors can release this immune "brake."

Simple explanation:

PD-L1 is part of a biological "off switch" for immune activity.

Some tumors exploit that switch.

PD-1/PD-L1 checkpoint inhibitors attempt to interfere with the switch so that T cells can recognize and attack cancer more effectively.

PD-1 vs PD-L1: What's the Difference?

PD-1 and PD-L1 are related but are not the same molecule.

Feature PD-1 PD-L1
Full name Programmed cell death protein 1 Programmed death-ligand 1
Type Immune checkpoint receptor Immune checkpoint ligand
Common location T cells and other immune cells Various cells, including some tumor and immune cells
Interaction Binds PD-L1 and related ligands Binds PD-1
Cancer significance Can suppress T-cell activity when activated by its ligands Can contribute to tumor immune evasion
Therapeutic strategy PD-1 inhibitors block the receptor PD-L1 inhibitors block the ligand

Thus, PD-1 and PD-L1 are two sides of the same immune-checkpoint pathway.

How the PD-1/PD-L1 Checkpoint Works

The immune system needs mechanisms that prevent excessive immune activation. Checkpoint pathways are part of that control system.

In simplified form:

T CELL
↓
RECOGNIZES POTENTIAL TARGET
↓
PD-1 ↔ PD-L1
↓
IMMUNE SIGNAL IS DAMPENED
↓
LESS T-CELL ATTACK

Cancer can take advantage of this normal regulatory mechanism.

If a tumor expresses PD-L1, the PD-1/PD-L1 interaction can contribute to an immunosuppressive environment around the cancer.

Checkpoint inhibitors interfere with this signaling pathway. NCI explains that blocking PD-1 or PD-L1 can allow T cells to resume cancer-killing activity. NCI: Immune Checkpoint Inhibitors.

Why Cancer Cells Use PD-L1

Cancer is an evolutionary disease. Tumor cells that successfully evade immune attack can gain a survival advantage.

PD-L1 expression can therefore be viewed as one component of a broader tumor immune-evasion strategy.

But PD-L1 is only one part of the tumor microenvironment.

Other factors include:

  • T-cell infiltration
  • Antigen presentation
  • Tumor mutational landscape
  • Interferon signaling
  • Myeloid-cell populations
  • Regulatory T cells
  • Cytokines
  • Cancer-associated fibroblasts
  • Metabolic conditions within the tumor
  • Other immune checkpoints

This helps explain why PD-L1 alone cannot perfectly predict immunotherapy response.

How Is PD-L1 Tested?

PD-L1 is generally measured using immunohistochemistry (IHC) on tumor tissue.

The test uses antibodies designed to detect PD-L1 protein in a tissue specimen.

The result is then quantified according to a scoring system appropriate for the particular cancer, assay and treatment.

TUMOR BIOPSY
↓
TISSUE PROCESSING
↓
PD-L1 ANTIBODY STAINING
↓
MICROSCOPIC / DIGITAL PATHOLOGY ASSESSMENT
↓
PD-L1 SCORE
↓
CLINICAL INTERPRETATION

PD-L1 testing is not simply a matter of asking whether a tumor is "positive" or "negative." The assay, scoring method, cutoff and treatment indication all matter.

PD-L1 Immunohistochemistry

Immunohistochemistry detects proteins in tissue using antibodies.

For PD-L1 testing, the pathologist evaluates staining patterns in the tumor and/or relevant immune cells depending on the assay and indication.

Different approved assays use different antibody clones and may have different scoring systems and clinical cutoffs.

The FDA maintains a current list of authorized companion diagnostic devices. Its 2026 database includes multiple PD-L1 assays and indication-specific cutoffs, demonstrating why PD-L1 results must be interpreted in the context of the specific test and treatment. FDA: Authorized Companion Diagnostics.

What Is TPS?

TPS stands for Tumor Proportion Score.

TPS is used in several clinical contexts, particularly in non-small cell lung cancer.

In simplified terms, TPS represents the percentage of viable tumor cells showing PD-L1 membrane staining among the evaluable tumor cells.

Example:

If a report says:

PD-L1 TPS = 60%

that means the assay identified PD-L1 expression on approximately 60% of the evaluable tumor cells according to the test's scoring methodology.

It does not mean that 60% of the patient's entire cancer is guaranteed to respond to immunotherapy.

It is a biomarker measurement, not a treatment-response probability.

What Is CPS?

CPS stands for Combined Positive Score.

Unlike TPS, CPS can incorporate PD-L1-positive tumor cells and relevant PD-L1-positive immune cells relative to the total number of viable tumor cells.

A simplified representation is:

CPS =
PD-L1-positive tumor cells + relevant PD-L1-positive immune cells
÷
Total viable tumor cells
× 100

The exact interpretation and clinically relevant cutoff depend on the cancer, assay and treatment indication.

For example, FDA records show that PD-L1 IHC 22C3 pharmDx has indication-specific CPS thresholds in several cancers, including certain gastric/GEJ, cervical and head-and-neck cancer settings. FDA PD-L1 22C3 information.

Do not compare TPS and CPS as if they were the same scale. They measure PD-L1 using different scoring concepts.

What Is Immune-Cell Scoring?

Some PD-L1 assays evaluate PD-L1 expression on immune cells within the tumor microenvironment.

This is particularly important for certain cancer types and specific assays.

For example, FDA documentation for the SP142 assay includes scoring based on the proportion of tumor area occupied by PD-L1-positive immune cells in certain indications. FDA SP142 assay information.

This illustrates an important principle:

PD-L1 testing is not one universal test with one universal cutoff.

The clinically meaningful score depends on:

  • Cancer type
  • Assay
  • Antibody clone
  • Scoring method
  • Cutoff
  • Therapy
  • Clinical setting

PD-L1 Assays and Clones

Several PD-L1 IHC assays are used in clinical oncology.

Examples include:

  • 22C3
  • 28-8
  • SP263
  • SP142

These assays should not automatically be treated as interchangeable.

The FDA's companion-diagnostic database documents indication-specific uses for different PD-L1 assays, including different cutoffs and therapeutic associations. FDA companion diagnostic database.

SmartCancer rule: When reading a PD-L1 report, record the assay + clone + score + scoring method + cutoff + cancer type + intended treatment.

What Does PD-L1 Positive Mean?

A "PD-L1-positive" result means that PD-L1 expression meets the relevant definition or threshold for the assay and clinical context.

It does not mean:

  • Immunotherapy will definitely work.
  • The cancer will disappear.
  • Cancer cells are completely dependent on PD-L1.
  • All tumor cells express PD-L1.
  • Other biomarkers are irrelevant.
  • Chemotherapy or targeted therapy is necessarily inappropriate.

Instead, PD-L1 positivity may indicate that an immunotherapy strategy is more clinically relevant in a particular treatment setting.

The exact implication depends on the cancer and the treatment being considered.

What Does PD-L1 Negative Mean?

PD-L1 negative does not necessarily mean "immunotherapy won't work."

PD-L1 is an imperfect predictive biomarker.

A tumor can have low or undetectable PD-L1 expression and still respond to an immune checkpoint inhibitor in some clinical settings.

Conversely, a tumor with high PD-L1 expression may fail to respond.

NCI notes that PD-L1 and other currently used immunotherapy biomarkers do not perfectly predict response to immune checkpoint inhibitors. NCI: Predicting response to immunotherapy.

Think probability, not certainty.

PD-L1 can shift the probability of benefit. It does not determine the patient's future with certainty.

What Does High PD-L1 Mean?

High PD-L1 expression generally indicates that a substantial proportion of the relevant cells demonstrate PD-L1 expression according to the test's scoring system.

In some cancers and treatment settings, higher PD-L1 expression is associated with greater likelihood of benefit from particular checkpoint inhibitors.

But "high" is not a universal number.

For example, FDA-authorized PD-L1 tests can use thresholds such as:

  • TPS ≥1%
  • TPS ≥50%
  • CPS ≥1
  • CPS ≥10
  • Immune-cell scoring thresholds

These thresholds are indication-specific, not universal definitions of "high PD-L1." FDA records demonstrate that different therapies and cancers use different PD-L1 thresholds. FDA authorized companion diagnostics.

Which Cancers Use PD-L1 Testing?

PD-L1 testing is clinically relevant in multiple cancer types.

NCI lists PD-L1 among tumor-marker tests used in cancers including:

  • Non-small cell lung cancer
  • Triple-negative breast cancer
  • Liver cancer
  • Stomach cancer
  • Gastroesophageal junction cancer
  • Cervical cancer
  • Bladder and urothelial cancers
  • Head and neck cancers
  • Classical Hodgkin lymphoma
  • Other selected cancers

However, the clinical role of PD-L1 testing differs substantially between these diseases. NCI: Tumor Marker Tests in Common Use.

PD-L1 in Lung Cancer

Non-small cell lung cancer is one of the most important settings for PD-L1 testing.

PD-L1 can be reported using TPS.

Depending on histology, stage, molecular profile and treatment setting, PD-L1 results can influence decisions involving immune checkpoint inhibitors.

Importantly, advanced NSCLC should generally be evaluated using a broader biomarker strategy rather than PD-L1 alone.

Relevant molecular testing may include biomarkers such as:

  • EGFR
  • ALK
  • ROS1
  • KRAS
  • BRAF
  • MET
  • RET
  • NTRK
  • HER2
  • PD-L1

SmartCancer principle: In advanced NSCLC, PD-L1 is one node in the molecular decision tree, not the entire decision tree.

FDA records demonstrate that specific PD-L1 assays can be linked to specific treatment indications and thresholds in NSCLC. For example, FDA documentation includes TPS-based thresholds for several PD-L1 companion-diagnostic applications. FDA SP263 example.

PD-L1 in Breast Cancer

PD-L1 testing is particularly relevant to certain triple-negative breast cancer (TNBC) treatment decisions.

Depending on the therapeutic indication, PD-L1 may be evaluated using an immune-cell scoring approach or another validated assay.

This is a good example of why patients should not assume that a PD-L1 score from one cancer type can be interpreted using the same cutoff used for another.

PD-L1 in Gastric and Esophageal Cancer

PD-L1 can be relevant to immunotherapy decisions in selected gastric, gastroesophageal junction and esophageal cancers.

CPS is commonly important in these settings.

FDA records include PD-L1 IHC 22C3 and 28-8 companion-diagnostic applications using CPS thresholds in selected gastric, GEJ and esophageal indications. FDA companion-diagnostic list.

PD-L1 in Bladder and Urothelial Cancer

PD-L1 testing has also been used in selected urothelial-cancer treatment settings.

Depending on the treatment, assay and indication, scoring can involve tumor cells, immune cells or CPS.

Therefore, the exact treatment implications should always be tied to the specific assay and current drug indication.

PD-L1 in Head and Neck Cancer

PD-L1 can be relevant to treatment decisions in head and neck squamous cell carcinoma.

CPS is used in certain clinical contexts.

FDA documentation includes PD-L1 IHC 22C3 applications using CPS-based thresholds for selected head-and-neck cancer treatment decisions. FDA 22C3 documentation.

PD-L1 in Cervical Cancer

PD-L1 testing can be relevant in selected cervical-cancer immunotherapy decisions.

In applicable settings, CPS may be used rather than TPS.

This again demonstrates the central rule of PD-L1 interpretation:

PD-L1 RESULT
+
CANCER TYPE
+
ASSAY
+
SCORING METHOD
+
TREATMENT
=
CLINICAL MEANING

PD-L1 in Other Cancers

PD-L1 can also be relevant in other malignancies, including selected liver cancers, lymphomas and additional tumor types.

However, the role of PD-L1 testing continues to evolve as clinical trials refine which patients benefit from checkpoint blockade and which combinations are most effective.

PD-L1 and Immunotherapy

PD-L1 is primarily important because it intersects with immune checkpoint inhibition.

Immune checkpoint inhibitors can target either side of the pathway:

PD-1 Inhibitors

Block the PD-1 receptor on immune cells.

PD-L1 Inhibitors

Block PD-L1 and interfere with its interaction with PD-1.

The therapeutic objective is broadly similar: reduce inhibitory signaling so that anti-tumor immune activity can occur.

PD-1 and PD-L1 Inhibitors

Examples of immune checkpoint inhibitors targeting the pathway include:

  • Pembrolizumab — PD-1 inhibitor
  • Nivolumab — PD-1 inhibitor
  • Cemiplimab — PD-1 inhibitor
  • Durvalumab — PD-L1 inhibitor
  • Atezolizumab — PD-L1 inhibitor
  • Avelumab — PD-L1 inhibitor

This list is illustrative rather than a treatment recommendation. Specific approvals, combinations, indications and biomarker requirements vary by cancer and jurisdiction.

Does PD-L1 Predict Response to Immunotherapy?

Yes, but imperfectly.

PD-L1 is a predictive biomarker in certain clinical contexts, but it is not a perfect predictor of response.

Why?

Because effective anti-tumor immunity depends on many biological steps.

TUMOR ANTIGENS
↓
ANTIGEN PRESENTATION
↓
T-CELL ACTIVATION
↓
T-CELL TRAFFICKING
↓
TUMOR INFILTRATION
↓
CHECKPOINT SIGNALING
↓
T-CELL KILLING

PD-L1 represents only one component of this system.

NCI has noted that currently used predictive biomarkers such as PD-L1 and TMB do not accurately predict immunotherapy response in every patient. NCI: Immunotherapy response prediction.

Why PD-L1 Is an Imperfect Biomarker

1. Tumor heterogeneity

Not every cancer cell necessarily expresses PD-L1 at the same level.

2. Spatial variation

PD-L1 expression can differ between different regions of a tumor or between primary and metastatic sites.

3. Temporal variation

PD-L1 expression can change over time, including in response to treatment or immune signaling.

4. Assay differences

Different assays use different antibodies, scoring systems and thresholds.

5. Tumor microenvironment

Immune cells and other components of the tumor microenvironment can affect response independently of PD-L1.

6. Alternative immune-suppression mechanisms

Tumors can use multiple immune-evasion pathways simultaneously.

7. Technical limitations

A biopsy may contain insufficient tumor or may not represent the biology of every cancer site.

8. Biological complexity

PD-L1 expression does not tell the entire story of whether a patient's immune system can recognize and eliminate the tumor.

Bottom line: PD-L1 should be interpreted as one component of a multidimensional cancer-biology profile—not as a simple "immunotherapy yes/no" switch.

PD-L1 and Immunotherapy Resistance

Even when a tumor initially responds to checkpoint inhibition, resistance can develop.

Resistance may involve changes at several biological levels:

  • Loss or alteration of tumor antigens
  • Defects in antigen presentation
  • Changes in interferon signaling
  • Alternative immune checkpoints
  • Changes in the tumor microenvironment
  • Immunosuppressive cell populations
  • Tumor evolution
  • Changes in PD-L1 expression itself
INITIAL BIOMARKER
↓
IMMUNOTHERAPY
↓
TUMOR RESPONSE
↓
SELECTIVE PRESSURE
↓
TUMOR EVOLUTION
↓
IMMUNE RESISTANCE
↓
NEW BIOLOGY

This is why SmartCancer treats biomarkers as dynamic nodes rather than permanent labels.

PD-L1 vs Other Immunotherapy Biomarkers

PD-L1 is only one of several biomarkers used to understand potential response to immune checkpoint inhibitors.

Biomarker What It Measures General Relevance
PD-L1 PD-L1 protein expression Immunotherapy selection in selected cancers
MSI-H Microsatellite instability Important immunotherapy biomarker in selected settings
dMMR Mismatch-repair deficiency Associated with MSI in many tumors and relevant to immunotherapy
TMB Number of mutations in tumor DNA Predictive information in selected contexts
Gene-expression signatures Patterns of gene activity Emerging / research and selected clinical applications
Immune-cell infiltration Presence and characteristics of immune cells Important biological context

This is one reason SmartCancer's Biomarkers Pillar should connect PD-L1 to the broader biomarker network rather than treating it as an isolated test.

How to Read a PD-L1 Report

When reviewing a PD-L1 result, identify these elements:

  1. Cancer type
  2. Specimen source
  3. Assay
  4. Antibody clone
  5. Scoring method
  6. PD-L1 score
  7. Cutoff
  8. Treatment under consideration
  9. Other biomarkers
  10. Clinical context

Example:

A report stating "PD-L1 TPS 70%" is not enough information to determine treatment by itself.

You still need to know:

  • What cancer?
  • What stage?
  • What assay?
  • What treatment?
  • Are there other actionable biomarkers?
  • Is the sample representative?
  • What treatment has already been given?

PD-L1 Testing and Pathology Quality

Because PD-L1 results can influence treatment decisions, laboratory and pathology quality are important.

The interpretation should be performed using the validated methodology appropriate for the specific assay and indication.

The FDA emphasizes that companion diagnostics provide information essential to the safe and effective use of corresponding therapies, and inaccurate diagnostic results can lead to suboptimal treatment decisions. FDA: Companion Diagnostics.

PD-L1 and Clinical Trials

PD-L1 is also important in cancer research.

Clinical trials may investigate:

  • PD-1 inhibitors
  • PD-L1 inhibitors
  • Combination checkpoint blockade
  • Checkpoint inhibitors plus chemotherapy
  • Checkpoint inhibitors plus targeted therapy
  • Checkpoint inhibitors plus radiation
  • Checkpoint inhibitors plus antibody-drug conjugates
  • Novel immune checkpoints
  • Biomarker-guided treatment sequencing
  • New biomarkers that outperform PD-L1

The NCI clinical-trial database includes active studies investigating PD(L)-1-based therapies and biomarkers intended to predict immunotherapy response. NCI clinical trials involving anti-PD-L1 therapy.

PD-L1 in the SmartCancer Oncology Knowledge Graph

PD-L1 should function as a major node in the SmartCancer Oncology Knowledge Graph.

PD-L1
↓
PD-1 / PD-L1 PATHWAY
↓
IMMUNE EVASION
↓
PD-L1 IHC
↓
TPS / CPS / IC SCORE
↓
IMMUNOTHERAPY
↓
RESPONSE
↓
PRIMARY / ACQUIRED RESISTANCE
↓
NEXT-LINE STRATEGY
↓
CLINICAL TRIAL

PD-L1 Cross-Links

Replace the placeholder URLs above with the final SmartCancer URLs when those cluster pages are published.

The Future of PD-L1 Testing

The future of immunotherapy biomarker science is unlikely to depend on PD-L1 alone.

Researchers are investigating increasingly sophisticated approaches that combine multiple biological signals.

Multi-Biomarker Models

Combining PD-L1 with genomic, clinical and immune features.

AI-Powered Prediction

Machine-learning models may identify complex response patterns that single biomarkers miss.

Spatial Biology

Analyzing where PD-L1 and immune cells occur within the tumor.

Digital Pathology

Computational analysis of tissue architecture and biomarker expression.

Dynamic Biomarkers

Measuring how immune biology changes during treatment.

ctDNA Integration

Combining molecular disease monitoring with immune biomarkers.

The long-term objective is not simply to determine whether PD-L1 is positive.

It is to answer a much more useful question:

Given this patient's cancer, molecular profile, immune environment, treatment history and current disease state, what treatment strategy has the strongest evidence of benefit?

PD-L1: The Most Important Takeaways

  • PD-L1 is an immune checkpoint ligand.
  • PD-L1 can bind PD-1 and suppress T-cell activity.
  • Some cancers exploit this pathway for immune evasion.
  • Checkpoint inhibitors can block PD-1/PD-L1 signaling.
  • PD-L1 is commonly measured by immunohistochemistry.
  • TPS and CPS are different scoring systems.
  • PD-L1 cutoffs are cancer- and treatment-specific.
  • Different PD-L1 assays are not automatically interchangeable.
  • PD-L1 positivity does not guarantee response.
  • PD-L1 negativity does not necessarily eliminate immunotherapy as an option.
  • PD-L1 is only one component of the immunotherapy biomarker landscape.
  • MSI-H, dMMR, TMB and other biological factors can also matter.
  • Tumor biology can evolve, including during treatment.
  • The most useful PD-L1 interpretation is cancer-specific and treatment-specific.

Frequently Asked Questions About PD-L1

What does PD-L1 stand for?

PD-L1 stands for programmed death-ligand 1. It is an immune-regulatory protein that can suppress T-cell activity when it interacts with PD-1.

Is PD-L1 a cancer gene?

PD-L1 is a protein encoded by the CD274 gene. It is better understood as an immune-checkpoint ligand rather than simply as a conventional cancer-driving gene.

What does PD-L1 positive mean?

It means that PD-L1 expression meets the relevant threshold according to the assay and scoring system used. The treatment significance depends on the cancer, therapy and clinical setting.

What does PD-L1 negative mean?

It means that PD-L1 expression did not meet the relevant test threshold. It does not necessarily mean that immunotherapy cannot work.

What is PD-L1 TPS?

TPS, or Tumor Proportion Score, estimates the percentage of viable tumor cells showing PD-L1 membrane staining according to the relevant assay.

What is PD-L1 CPS?

CPS, or Combined Positive Score, incorporates PD-L1-positive tumor cells and relevant immune cells relative to the total number of viable tumor cells, according to the assay methodology.

Is TPS the same as CPS?

No. TPS and CPS are different scoring systems and should not be directly compared.

What is a high PD-L1 score?

There is no universal definition. The clinically meaningful threshold depends on the cancer, assay, scoring method and treatment indication.

Can PD-L1 change over time?

Yes. Tumor biology can evolve, and PD-L1 expression can vary between tumor sites and over the course of treatment.

Does high PD-L1 guarantee immunotherapy response?

No. PD-L1 is an imperfect predictive biomarker. Other characteristics of the tumor and immune microenvironment can affect response.

Can someone with PD-L1-negative cancer receive immunotherapy?

In some clinical settings, yes. The answer depends on the cancer, treatment, regulatory indication and other biomarkers.

Is PD-L1 the same as PD-1?

No. PD-L1 is the ligand; PD-1 is the receptor. They interact as part of an immune-checkpoint pathway.

Which cancers use PD-L1 testing?

PD-L1 testing is used in selected treatment settings across multiple cancers, including certain lung, breast, gastric, esophageal, urothelial, cervical and head-and-neck cancers, among others.

Can PD-L1 testing identify a clinical trial?

Yes. Some trials use PD-L1 or other immune biomarkers as eligibility or stratification criteria.

Conclusion: PD-L1 Is a Biomarker, Not a Verdict

PD-L1 has become one of the most important biomarkers in cancer immunotherapy because it provides a window into one mechanism by which tumors can suppress immune attack.

But PD-L1 should never be reduced to a simplistic "positive equals immunotherapy" or "negative equals no immunotherapy" rule.

The clinically meaningful interpretation is more sophisticated:

CANCER TYPE
+
STAGE
+
PD-L1 ASSAY
+
TPS / CPS / IC SCORE
+
OTHER BIOMARKERS
+
PREVIOUS TREATMENT
+
TUMOR BIOLOGY
+
CLINICAL CONTEXT
↓
PRECISION IMMUNOTHERAPY DECISION

That is the role PD-L1 should occupy within the SmartCancer Oncology Knowledge Graph: not as an isolated laboratory number, but as a biological node connecting the tumor, immune system, treatment, response and resistance.

Medical disclaimer: This article is an educational resource and is not medical advice. PD-L1 results should be interpreted by qualified pathology and oncology professionals in the context of the specific cancer, stage, assay, treatment indication and current evidence. Drug approvals and biomarker requirements can change over time and vary by jurisdiction. A PD-L1 result does not guarantee treatment response or determine an individual treatment plan.

SmartCancer Oncology Knowledge Graph
Biomarkers → PD-L1 → Immunotherapy → Treatment Response → Resistance → Clinical Trials

Labels:

Comments

Post a Comment

Popular Posts